Molecular imaging's full potential in health care will not be realized until education of clinicians catches up with advances in the field, according to Robert Gillies of the Moffitt Cancer Center in Tampa, Fla. "There really aren't enough senior-level people to do a full-out establishment of a new track in radiology, but we see this as inevitable," he said, noting that some institutions are ahead of the curve. Meanwhile, Dr. Anthony Shields of Wayne State University argues that molecular imaging is radically changing drug development, but James Basilion of Case Western Reserve University says meeting the bar for FDA approval and then CMS payment is challenging. "Trying to prove that an agent will change treatment ... is extremely difficult," Basilion said, citing the example of amyloid imaging.

Related Summaries